loading
Amicus Therapeutics Inc stock is traded at $6.06, with a volume of 3.51M. It is down -3.50% in the last 24 hours and up +7.07% over the past month. Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$6.28
Open:
$6.27
24h Volume:
3.51M
Relative Volume:
0.71
Market Cap:
$1.87B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-17.82
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+1.68%
1M Performance:
+7.07%
6M Performance:
-36.94%
1Y Performance:
-40.94%
1-Day Range:
Value
$5.97
$6.29
1-Week Range:
Value
$5.95
$6.37
52-Week Range:
Value
$5.51
$12.65

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name
Name
Amicus Therapeutics Inc
Name
Phone
(609) 662-2000
Name
Address
47 HULFISH STREET, PRINCETON, NJ
Name
Employee
499
Name
Twitter
@amicusrx1
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
FOLD's Discussions on Twitter

Compare FOLD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FOLD
Amicus Therapeutics Inc
6.06 1.93B 493.67M -104.69M -31.51M -0.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-17-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-13-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-06-24 Initiated Jefferies Buy
May-30-24 Initiated Wells Fargo Overweight
May-14-24 Upgrade Guggenheim Neutral → Buy
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-09-22 Initiated Morgan Stanley Equal-Weight
Apr-13-22 Resumed Goldman Neutral
Jan-14-22 Upgrade SVB Leerink Mkt Perform → Outperform
Nov-15-21 Upgrade Stifel Hold → Buy
Sep-30-21 Upgrade JP Morgan Neutral → Overweight
Jul-19-21 Resumed BTIG Research Buy
May-27-21 Initiated Needham Hold
May-21-21 Initiated UBS Buy
Apr-14-21 Upgrade Cantor Fitzgerald Neutral → Overweight
Mar-02-21 Initiated Stifel Hold
Feb-12-21 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-12-21 Downgrade JP Morgan Overweight → Neutral
Dec-28-20 Resumed Cantor Fitzgerald Overweight
Dec-10-20 Downgrade Citigroup Buy → Neutral
Nov-11-20 Initiated Berenberg Hold
Jun-17-20 Initiated BTIG Research Buy
Feb-04-20 Resumed Cantor Fitzgerald Overweight
Nov-12-19 Reiterated H.C. Wainwright Buy
Jun-17-19 Initiated H.C. Wainwright Buy
Jun-05-19 Reiterated Cantor Fitzgerald Overweight
Apr-05-19 Initiated Janney Buy
Jan-30-19 Initiated Cantor Fitzgerald Overweight
Oct-29-18 Initiated Citigroup Neutral
Aug-17-18 Downgrade Chardan Capital Markets Buy → Neutral
Oct-06-17 Resumed Goldman Neutral
Sep-13-17 Reiterated Chardan Capital Markets Buy
Aug-10-17 Reiterated Chardan Capital Markets Buy
Jan-24-17 Upgrade Robert W. Baird Neutral → Outperform
May-18-16 Initiated BofA/Merrill Buy
Apr-14-16 Initiated Robert W. Baird Neutral
Apr-12-16 Reiterated Chardan Capital Markets Buy
Sep-16-15 Downgrade Chardan Capital Markets Buy → Neutral
Jun-16-15 Reiterated Chardan Capital Markets Buy
View All

Amicus Therapeutics Inc Stock (FOLD) Latest News

pulisher
04:51 AM

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Legato Capital Management LLC - MarketBeat

04:51 AM
pulisher
Jul 24, 2025

Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - Insider Monkey

Jul 24, 2025
pulisher
Jul 24, 2025

Amicus Therapeutics Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

How Amicus Therapeutics Inc. stock reacts to Fed policy changesFree Investment Portfolio Suggestions - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday - MarketBeat

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Amicus Therapeutics Inc. stock priceExceptional profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Edgestream Partners L.P. Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Amicus Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-23 00:04:03 - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Amicus Therapeutics Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 21, 2025

Amicus Therapeutics Sets Date for Q2 Earnings: Key Updates Expected from Rare Disease Pipeline - Stock Titan

Jul 21, 2025
pulisher
Jul 20, 2025

Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Morgan Stanley - MarketBeat

Jul 20, 2025
pulisher
Jul 20, 2025

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpWhat's Next? - MarketBeat

Jul 20, 2025
pulisher
Jul 19, 2025

Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda - MSN

Jul 19, 2025
pulisher
Jul 17, 2025

Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching - MSN

Jul 17, 2025
pulisher
Jul 17, 2025

Amicus stock gains as Morgan Stanley upgrades (FOLD:NASDAQ) - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

Amicus Therapeutics: A Biotech Buy with Legal, Product, and Market Catalysts - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Amicus Therapeutics (FOLD) Soars 10.05% on Japan Approval - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Rice Hall James & Associates LLC Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jul 17, 2025
pulisher
Jul 17, 2025

Amicus Therapeutics stock upgraded to Overweight by Morgan Stanley on IP strength - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Stephens Investment Management Group LLC Makes New $5 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jul 17, 2025
pulisher
Jul 16, 2025

10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey

Jul 16, 2025

Amicus Therapeutics Inc Stock (FOLD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):